Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 8, 2019

Mirati and Bristol-Myers Squibb team up for NSCLC drug trial

Mirati Therapeutics has formed a clinical collaboration with Bristol-Myers Squibb Company to assess sitravatinib in combination with nivolumab (OPDIVO) for the treatment of patients with second line non-small cell lung cancer (NSCLC).

Mirati Therapeutics has formed a clinical collaboration with Bristol-Myers Squibb Company to assess sitravatinib in combination with nivolumab (OPDIVO) for the treatment of patients with second-line non-small cell lung cancer (NSCLC).

Mirati will sponsor and fund the clinical trial, while Bristol-Myers Squibb will provide nivolumab free of cost.

The collaboration involves Mirati’s proposed Phase III pivotal trial in second-line NSCLC patients who have progressed after being treated with a platinum-based regimen and a checkpoint inhibitor.

The trial is scheduled to begin in the first half of this year and will see patients randomised to receive either the combination of sitravatinib and nivolumab or single-agent docetaxel.

An interim analysis of overall response rate (ORR) will be included in the trial to obtain accelerated approval.

“Our Phase II clinical trial of sitravatinib plus nivolumab in patients with checkpoint refractory NSCLC has shown promising activity.”

The primary endpoint of the Phase III trial will be overall survival.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Mirati Therapeutics president and CEO Charles Baum said: “Our Phase II clinical trial of sitravatinib plus nivolumab in patients with checkpoint refractory NSCLC has shown promising activity and a well-tolerated safety profile.

“The trial is expected to result in a new drug application (NDA) for sitravatinib for the treatment of NSCLC patients whose tumours have progressed following treatment with a platinum-containing regimen and a checkpoint inhibitor.

“This collaboration further validates the potential of sitravatinib and allows Mirati to invest in and expand the development of our clinical and pre-clinical programmes.”

Sitravatinib is a spectrum-selective kinase inhibitor that has the ability to inhibit receptor tyrosine kinases (RTKs), such as TAM family receptors, split family receptors, and RET.

Mirati currently owns the global development and commercial rights to sitravatinib outside certain Asian countries, where it is partnered with BeiGene.

The company can also develop the drug programme in combination with other agents.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU